Buscar en
Revista Argentina de Microbiología
Toda la web
Inicio Revista Argentina de Microbiología First report of a clinical isolate of blaOXA-48- carbapenemase producing Raoulte...
Información de la revista
Vol. 52. Núm. 1.
Páginas 82-83 (Enero - Marzo 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
369
Vol. 52. Núm. 1.
Páginas 82-83 (Enero - Marzo 2020)
Letter to the Editor
DOI: 10.1016/j.ram.2019.02.002
Open Access
First report of a clinical isolate of blaOXA-48- carbapenemase producing Raoultella ornithinolytica in South America
Primer reporte de un aislado clínico de Raoultella ornithinolytica productora de carbapenemasa blaOXA-48 en América del Sur
Visitas
...
Jorge A. Reyesa,b,
Autor para correspondencia
jorgereyes83@gmail.com

Corresponding author.
, Fernando Villavicencioc, José E. Villacísd, Evelyn Pavóne, Natalia Campoverdee, Mauricio Espinele, Byron Núñeze, Gabriel Truebab
a Facultad de Ciencias Químicas. Universidad Central del Ecuador, Quito, Ecuador
b Instituto de Microbiología, colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Ecuador
c Centro de Referencia Nacional de Resistencia a los Antimicrobianos, Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”, Quito, Ecuador
d Carrera de Bioquímica Clínica, Facultad de Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador
e Hospital de especialidades Carlos Andrade Marín, Quito, Ecuador
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Antibiotic sensitivity tests, carbapenemase assays and carbapenemase gene detection in an Ecuadorian Raoultella ornithinolytica isolate
Texto completo
Dear Editor:

Raoultella spp., a bacterium named after Didier Raoult, is a Gram-negative belonging to the Enterobacteriaceae family. There have been described 4 species: Raoultella planticola, Raoultella ornithinolytica, Raoultella terrigena, and Raoultella electrica, all species are inhabitants of soil and plants. Recently, R. planticola and R. ornithinolytica have been associated with human infections and resistance to different antibiotics including carbapenems5. In this report, we describe an infection caused by blaOXA-48 producing R. ornithinolytica. A 64-year-old male patient was admitted into a 700-bed hospital in Quito, in order to restore intestinal transit after ileocecal resection. Two days after admission the patient presented sepsis characterized by hypotension, fever, and leukocytosis. The patient was directed to intensive care unit where he was treated with Ampicillin/sulbactam for 10 days, subsequent blood cultures were negative however Escherichia coli was recovered from tracheal aspirate. The patient was submitted to the surgical department to continue treatment and 10 days late he presented a surgical site infection, R. planticola (resistant to imipenem and piperacillin/tazobactam but susceptible to third generation cephalosporins and ciprofloxacin) was isolated and detected using a Vitek® compact 2 system (Biomeriux, France), CARD AST 272 (Table 1). The patient was treated with ciprofloxacin 500mg i.v. q12h and recovered satisfactorily.

Table 1.

Antibiotic sensitivity tests, carbapenemase assays and carbapenemase gene detection in an Ecuadorian Raoultella ornithinolytica isolate

Minimum inhibitory concentration (μg/ml) using vitek 2 systemCIM  Rapidec CarbaNP  PCR and sequencing
Amp/Sul  Pip/Taz  Cfz  Ctx  Imi  Mer  Cip  Ami  Col  Positive  Positive  Carbapenemase  MGE 
>32  >128  <1  <1  <0.25  ≤2  ≤0.5      blaOXA-48  Tn1999 

Amp/Sul: Ampicilin-sulbatam, Pip/Taz: Piperacilin-tazobactam, Cfz: Cefazidime, Ctx: Cefotaxime, Imi: Imipenem, Mer: Meropenem, Cip: Ciprofloxacin, Ami: Amikacin, Col: Colistin. CIM: Carbapenem inactivation method. MGE: Mobile genetic element. PCR: polymerase chain reaction.

Isolate analysis using DNA sequences of rpoB and 16S rRNA genes and MALDI-TOF Vitek MS system, (bioMérieux) indicated that the isolate was R. ornithinolytica (99.9% identification score). The RAPIDEC CARBA NP® (bioMérieux) assay was positive and polymerase chain reaction (PCR) amplifying the blaOXA-48 associated with Tn1999 was performed3. The amplicon was cleaned, using Wizard® SV gel, and sequenced in Macrogen (South Korea); nucleotide sequences showed the presence of blaOXA-48 gene (accession no.: MH507508) and Tn1999 (accession no.: MK359485). The amplicon showed 99% nucleotide identity to a Tn1999 harboring blaOXA-48 previously described in Klebsiella pneumoniae (accession no.: JN626286). We were unable to determine the plasmid incompatibility group (conjugation using E. coli J53 as the recipient was unsuccessful), nor could we establish whether the patient was colonized by R. ornithinolytica before the surgery. To the best of our knowledge, this is the first description of a clinical isolate of R. ornithinolytica harboring blaOXA-48 in Ecuador and possibly in South America. Nevertheless, blaOXA-48 genes in Enterobacteriaceae have been described in Latin American and Caribbean countries2. In Ecuador, a blaOXA-48-like gene was found previously in K. pneumoniae (accession number KY609322.1). The blaOXA-48-like gene has been found associated with 5 isoforms of Tn1999 in Enterobacteriaceae4; interestingly, an R. ornithinolytica strain containing blaOXA-48 associated with Tn1999.2 was detected in Lebanon1. The genetic closeness of Raoultella spp. and Klebsiella spp., may lead to misidentification using biochemical tests e.g., Vitek 2 system, the introduction of rpoB and 16S rRNA genes analysis and the new technology based in MALDI-TOF MS allowed us a correct identification to species level of Raoultella spp. Thus, our results underline the accuracy of MALDI-TOF MS in R. ornithinolytica identification. This report was approved by the institutional human ethics committee Cod: 02-01-2018-003.

Ethical approval

This study was approved by Ethics Committee in Humans of Carlos Andrade Marín hospital Cod: 02-01-2018-003.

Funding

This study was funding by Instituto Nacional de Investigación en Salud Pública “Dr. Leopoldo Izquieta Pérez”, Quito – Ecuador and Instituto de microbiología, Universidad San Francisco de Quito.

Contributions

JR and GT: conception, design of the study and drafting the article. EV, FV, EP, NC, ME: acquisition of data, analysis and interpretation. BN and GT revising critically for important intellectual content of article. GT: final approval of the version to be submitted.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgements

The authors thank the technical staff of microbiology laboratory of the Hospital Carlos Andrade Marín-Quito. Also we appreciate the collaboration of Dr. Luis Solorzano in the Hospital Luis Vernaza for making the MALDITOF MS available.

References
[1]
C. Al-Bayssari, A.O. Olaitan, T. Leangapichart, L. Okdah, F. Dabboussi, M. Hamze, J. Rolain.
Whole-genome sequence of a blaOXA-48-harboring Raoultella ornithinolytica clinical isolate from Lebanon.
Antimicrob Agents Chemother, 60 (2016), pp. 2548-2550
[2]
K. Escandón-Vargas, S. Reyes, S. Gutiérrez, M.V. Villegas.
The epidemiology of carbapenemases in Latin America and the Caribbean.
Expert Rev Anti Infect Ther, 15 (2016), pp. 277-297
[3]
T. Giani, V. Conte, V. Di Pilato, R. Aschbacher, C. Weber, C. Larcher, G. Rossolini.
Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative.
Antimicrob Agents Chemother, 56 (2012), pp. 2211-2213
[4]
A. Mairi, A. Pantel, A. Sotto, J.-P. Lavigne, A. Touati.
OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.
Eur J Clin Microbiol Infect Dis, 37 (2018), pp. 587-604
[5]
P. Seng, B. Boushab, F. Romain, F. Gouriet, N. Bruder, C. Martin, et al.
Emerging role of Raoultella ornithinolytica in human infections: a series of cases and review of the literature.
Int J Infect Dis., 45 (2016), pp. 65-71
Copyright © 2019. Asociación Argentina de Microbiología
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.